Division of Psychiatry Research, Zucker Hillside Hospital, Northwell Health, New York, New York.
Institute for Behavioral Science, Feinstein Institute for Medical Research, Manhasset, New York.
J Clin Psychiatry. 2022 Sep 5;83(5):21m14272. doi: 10.4088/JCP.21m14272.
Switching of antipsychotic medications, which are used for many psychiatric conditions, is common. However, reasons and clinical documentation of such switches have scarcely been studied. A systematic, retrospective review of prescription records and prescriber notes was conducted to characterize reasons for and types of antipsychotic switches at one hospital during inpatient or outpatient care, starting August 1, 2017, until 270 antipsychotic switches with type and reasons were collected, as required by power analysis. After removing 7 cases in which quetiapine was switched to a non-antipsychotic agent, 263 antipsychotic switches involving 195 unique subjects (median age = 31 [interquartile range, 24-47] years; schizophrenia = 36.9%, bipolar disorder = 27.7%, schizoaffective disorder = 18.5%) were analyzed. Frequent reasons for antipsychotic switch were intolerability (45.7%) and inefficacy/clinical worsening (17.6%). Reasons did not differ by race ( = .2644), age ( = .0621), or insurance type ( = .2970), but differed heterogeneously regarding different reasons by sex ( = .004). The most common reported switches were from second-generation oral antipsychotics (SGA-OAPs) to other SGA-OAPs (N = 155, 58.9%), mostly due to tolerability or inefficacy; second-generation long-acting injectable antipsychotics (SGA-LAIs) to SGA-OAPs (11%), mostly due to intolerability, patient preference, or insurance coverage problems; and SGA-OAPs to SGA-LAIs (10.7%) due to nonadherence. Reasons for antipsychotic switch were properly documented in 208 (79.1%) of the prescriber notes. In this retrospective chart review, switching varied by sex regarding reasons and occurred almost in half of the cases due to intolerability. Different reasons predominated in switches from SGA-OAP to SGA-OAP, SGA-LAI to SGA-OAP, and SGA-OAP to SGA-LAI. One in 5 switches were not properly documented, requiring attention.
抗精神病药物的转换在许多精神疾病中很常见。然而,这种转换的原因和临床记录却很少被研究过。本研究对一家医院的住院或门诊患者的处方记录和处方医生笔记进行了系统的回顾性分析,以描述 2017 年 8 月 1 日至 270 例抗精神病药物转换的原因和类型,这些转换需符合事先的统计分析要求。在去除 7 例将喹硫平转换为非抗精神病药物的病例后,共涉及 195 例患者(中位数年龄 31 [四分位距 24-47] 岁;精神分裂症 36.9%,双相情感障碍 27.7%,分裂情感性障碍 18.5%)的 263 例抗精神病药物转换被纳入分析。抗精神病药物转换的常见原因是不耐受(45.7%)和无效/临床恶化(17.6%)。种族(=.2644)、年龄(=.0621)或保险类型(=.2970)对转换原因无影响,但性别(=.004)对不同原因的影响存在异质性。最常见的报告转换是第二代口服抗精神病药物(SGA-OAPs)转换为其他 SGA-OAPs(N=155,58.9%),主要是由于不耐受或无效;第二代长效注射抗精神病药物(SGA-LAI)转换为 SGA-OAPs(11%),主要是由于不耐受、患者偏好或保险覆盖问题;以及 SGA-OAPs 转换为 SGA-LAI(10.7%)是由于不依从。在 208 份(79.1%)处方记录中,抗精神病药物转换的原因被正确记录。在本回顾性图表分析中,转换的原因在性别上存在差异,且近一半的病例是由于不耐受引起的。SGA-OAP 转换为 SGA-OAP、SGA-LAI 转换为 SGA-OAP 以及 SGA-OAP 转换为 SGA-LAI 这三种情况的转换原因不同。有 1/5 的转换没有被正确记录,需要引起关注。